Shalby Reports Q2 Revenue Growth YoY Following Strong Q1 Performance

Market snapshot: Shalby Limited reported Q2 revenue of ₹3.13 billion compared to ₹2.85 billion in the prior-year period (as stated in the source alert; not independently verified). The update follows the scheduled meeting of the company's Board of Directors on November 3, 2026, to consider quarterly financial performance.

Data Snapshot

• Shalby recorded consolidated total revenue of ₹338.64 crore in Q1 FY27, up 11.6% YoY from ₹303.4 crore in Q1 FY26.
• Consolidated EBITDA for Q1 FY27 reached ₹49 crore with an EBITDA margin of 14.5%.
• Shalby secured a 30-year operational lease for Asha Parekh Hospital in Santacruz, Mumbai, to set up a 175+ bed facility.

What's Changed

• Q1 FY27 consolidated total revenue rose 11.6% YoY to ₹338.64 crore from ₹303.4 crore in Q1 FY26.
• Q1 FY27 EBITDA margin moderated to 14.5% compared to 16.0% in Q1 FY26.

Key Takeaways

• Shalby reported Q2 revenue of ₹3.13 billion compared to ₹2.85 billion YoY (as stated in the source alert; not independently verified).
• Grounded Q1 FY27 top-line reached ₹338.64 crore, demonstrating sustained demand across multi-specialty hospital operations.
• Long-term capacity agreements, such as the Asha Parekh Hospital facility in Mumbai, reinforce regional expansion goals.

SAHI Perspective

Shalby's operational trajectory focuses on scaling multi-specialty healthcare delivery while expanding its dedicated medical implant manufacturing business. While news alert metrics indicate top-line growth in Q2 (as stated in the source alert; not independently verified), verified financial trends from Q1 FY27 confirm steady baseline revenue generation across core clinical verticals.

Market Implications

Steady revenue performance in healthcare services provides defensive characteristics within equity portfolios. Ongoing capital allocation toward expanding operational bed counts in primary regional hubs positions Shalby to absorb rising inpatient healthcare demand.

Trading Signals

Market Bias: Neutral

Market bias is Neutral as the Q2 revenue datapoint remains an unverified G3 input alert, though grounded Q1 FY27 revenue of ₹338.64 crore indicates a stable operational backdrop.

Overweight: Healthcare Services, Hospitals

Trigger Factors:

• Publication of detailed Q2 FY27 audited financial filings on exchange portals
• Average Revenue Per Occupied Bed (ARPOB) trend updates
• EBITDA margin expansion in the medical implants division

Time Horizon: Near-term (0-3 months)

Industry Context

The Indian hospital sector continues to benefit from structural growth drivers, including increased health insurance adoption, expanding medical tourism, and elevated demand for specialized surgical care such as joint replacements and oncology treatments.

Key Risks to Watch

• Potential regulatory price caps on high-volume medical procedures and devices
• Gestation period and ramp-up costs associated with new multi-specialty facilities
• Monsoon seasonality impact on elective surgery scheduling

Recent Developments

Shalby's Board of Directors scheduled a meeting on November 3, 2026, to review and approve Q2 FY27 financial results. Earlier, the healthcare provider secured a 30-year operational lease for Asha Parekh Hospital in Santacruz, Mumbai, to develop a 175+ bed multi-specialty facility.

Closing Insight

With strong brand equity in orthopedic and specialty care, Shalby's medium-term value creation depends on efficient execution of new bed additions and margin stability in manufacturing operations.

High Performance Trading with SAHI.